Latest Ratios: P/E Ratio -17.1x · EV/EBITDA 105.4x · ROE -4.2%. (2004–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.4B | $3.0B | $2.4B | $2.9B | $6.7B | $13.9B | $11.6B | $9.0B | $5.9B | $4.8B | $3.2B |
| Enterprise Value | $3.0B | $2.6B | $11.0B | $12.9B | $16.8B | $24.9B | $20.0B | $14.7B | $9.1B | $9.6B | $6.1B |
| P/E Ratio → | -17.12 | — | — | — | 7.43 | 21.29 | 26.90 | 24.26 | 5.83 | 16.80 | 14.30 |
| P/S Ratio | 3.47 | 3.09 | 2.38 | 3.37 | 4.32 | 9.03 | 9.25 | 10.39 | 7.51 | 6.85 | 5.93 |
| P/B Ratio | 0.74 | 0.65 | 0.49 | 0.38 | 0.78 | 1.65 | 1.57 | 1.29 | 1.29 | 1.26 | 0.99 |
| P/FCF | 14.62 | 13.02 | 9.66 | 5.81 | — | 18.69 | — | — | — | — | 10.99 |
| P/OCF | 14.62 | 13.02 | 9.66 | 5.81 | 9.03 | 17.18 | 18.71 | 18.30 | 13.11 | 13.30 | 12.13 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.67 | 11.07 | 14.81 | 10.92 | 16.09 | 16.02 | 16.88 | 11.64 | 13.64 | 11.21 |
| EV / EBITDA | 105.41 | 92.28 | 13.11 | 18.51 | 12.49 | 18.11 | 18.13 | 16.20 | 13.00 | 15.57 | 13.81 |
| EV / EBIT | — | — | 28.48 | 158.82 | 16.79 | 23.93 | 24.16 | 24.58 | 16.28 | 18.66 | 16.02 |
| EV / FCF | — | 11.23 | 44.88 | 25.52 | — | 33.32 | — | — | — | — | 20.76 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 97.3% | 95.2% | 97.0% | 97.5% | 98.0% | 97.2% | 98.8% | 99.2% | 99.5% |
| Operating Margin | — | — | 38.9% | 9.3% | 65.1% | 67.2% | — | 86.2% | 71.5% | 68.9% | 63.1% |
| Net Profit Margin | -20.4% | -20.4% | -242.1% | -63.8% | 58.5% | 42.5% | 34.5% | 43.1% | 129.6% | 41.1% | 41.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -4.2% | -4.2% | -38.7% | -6.9% | 10.6% | 8.3% | 6.0% | 6.5% | 24.2% | 8.2% | 8.4% |
| ROA | -1.4% | -1.4% | -14.8% | -2.9% | 4.5% | 3.5% | 2.8% | 3.2% | 11.4% | 3.8% | 3.7% |
| ROIC | — | — | 1.9% | 0.3% | 3.9% | 4.4% | — | 5.5% | 5.1% | 4.9% | 4.5% |
| ROCE | — | — | 2.6% | 0.5% | 5.3% | 5.7% | — | 6.6% | 6.4% | 6.5% | 5.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 1.86 | 1.34 | 1.21 | 1.35 | 1.23 | 1.01 | 0.89 | 1.29 | 0.90 |
| Debt / EBITDA | 4.57 | 4.57 | 10.68 | 14.66 | 7.72 | 8.29 | 8.16 | 7.84 | 5.78 | 8.02 | 6.69 |
| Net Debt / Equity | — | -0.09 | 1.79 | 1.31 | 1.18 | 1.29 | 1.15 | 0.80 | 0.71 | 1.25 | 0.88 |
| Net Debt / EBITDA | -14.69 | -14.69 | 10.28 | 14.30 | 7.54 | 7.95 | 7.66 | 6.23 | 4.62 | 7.75 | 6.50 |
| Debt / FCF | — | -1.79 | 35.22 | 19.71 | — | 14.63 | — | — | — | — | 9.77 |
| Interest Coverage | — | — | 0.92 | 0.20 | 2.72 | 2.63 | 2.32 | 2.51 | 2.51 | 2.91 | 2.37 |
Net cash position: cash ($541M) exceeds total debt ($128M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.77 | 9.77 | 1.55 | 0.71 | 1.09 | 7.49 | 9.20 | 15.48 | 4.90 | 1.90 | 1.13 |
| Quick Ratio | 9.77 | 9.77 | 1.55 | 0.71 | 1.09 | 7.49 | 9.20 | 15.48 | 5.19 | 2.14 | 1.33 |
| Cash Ratio | 3.66 | 3.66 | 0.39 | 0.13 | 0.15 | 0.76 | 1.25 | 5.02 | 3.77 | 0.75 | 0.37 |
| Asset Turnover | — | 0.06 | 0.07 | 0.05 | 0.08 | 0.08 | 0.07 | 0.06 | 0.09 | 0.08 | 0.08 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 13.5% | 20.9% | 10.5% | 4.6% | 4.9% | 4.6% | 6.2% | 6.8% | 6.8% |
| Payout Ratio | — | — | — | — | 77.4% | 98.1% | 131.6% | 109.9% | 35.8% | 112.7% | 97.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 13.5% | 4.7% | 3.7% | 4.1% | 17.2% | 6.0% | 7.0% |
| FCF Yield | 6.8% | 7.7% | 10.4% | 17.2% | — | 5.4% | — | — | — | — | 9.1% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 13.5% | 20.9% | 10.7% | 4.6% | 4.9% | 4.6% | 6.2% | 6.8% | 6.8% |
| Shares Outstanding | — | $601M | $600M | $599M | $599M | $590M | $530M | $428M | $366M | $350M | $261M |
Tenant credit and concentration
As reported in recent financial statements, the company's P/FFO multiple of 7.67x in 2025Q4 suggests that the market is pricing in significant long-term impairment risks, as the valuation remains heavily discounted compared to historical averages and broader healthcare REIT peers.
The compressed valuation multiple appears to be a direct consequence of persistent tenant credit volatility and the resulting uncertainty surrounding future FFO stability. Investors should monitor whether this discount represents a value opportunity or a permanent impairment of the underlying asset base given the ongoing portfolio restructuring.
According to quarterly data, the company's NOI margin fluctuated from 97.9% in 2023Q3 to a low of 67.7% in 2025Q2, indicating that property-level profitability is being severely pressured by rising operating costs and potential rent concessions granted to distressed hospital operators.
The extreme variance in NOI margins suggests that the company's core property-level income is no longer predictable, likely due to the financial distress of key tenants. This volatility complicates the assessment of organic growth and may indicate that the current portfolio is struggling to maintain historical profitability levels.
Based on reported financial statements, the FFO payout ratio reached 88.9% in 2025Q4, which, when combined with periods of negative AFFO, suggests that the dividend is currently being supported by capital recycling rather than recurring operational cash flow.
The reliance on asset divestitures to fund distributions appears to be a defensive measure that may not be sustainable over the long term. Investors should monitor the company's ability to generate positive, recurring AFFO, as the current payout structure leaves little room for operational errors or further tenant defaults.
As disclosed in quarterly filings, the company's debt-to-equity ratio reached 2.09 in 2025Q3, illustrating that despite aggressive divestiture efforts, the firm remains highly leveraged relative to its shrinking equity base and volatile earnings profile.
The elevated leverage profile appears to limit the company's ability to navigate further tenant-related credit adjustments without additional asset sales. The lack of consistent interest coverage, as evidenced by negative figures in several recent quarters, warrants further investigation into the firm's long-term refinancing risk.
As noted in industry research, the use of standard P/E ratios for MPW is deeply misleading because it fails to account for the massive non-cash depreciation and recurring asset impairments that fundamentally distort GAAP net income.
Analysts should prioritize FFO or AFFO metrics to better capture the company's actual cash-generating capacity, as GAAP earnings are currently obscured by significant write-downs. Relying on P/E ratios in this context likely leads to an inaccurate assessment of the company's true valuation and operational health.
Includes 30+ ratios · 22 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MPW stock.
Medical Properties Trust, Inc.'s current P/E ratio is -17.1x. The historical average is 22.1x.
Medical Properties Trust, Inc.'s current EV/EBITDA is 105.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 19.8x.
Medical Properties Trust, Inc.'s return on equity (ROE) is -4.2%. The historical average is 4.4%.
Based on historical data, Medical Properties Trust, Inc. is trading at a P/E of -17.1x. Compare with industry peers and growth rates for a complete picture.
Medical Properties Trust, Inc.'s Debt/EBITDA ratio is 4.6x, indicating high leverage. A ratio above 4x may signal elevated financial risk.